MATCHER Data-Driven Innovation 2024

2 Apr – 28 Nov 2024 | Italy

Register
Register
Register

Vera Codazzi

Innovation Network Manager

Chiesi Farmaceutici

Parma, Italy

23 profile visitsER corporate representative (MATCH.POINT)

My organisation

Chiesi Farmaceutici

Chiesi Farmaceutici

Emilia-Romagna corporate

Parma, Italy

Chiesi Farmaceutici is an international group based in Parma, research-oriented, with over 85 years of experience, present in 31 countries. The Chiesi Group researches, develops and markets innovative drugs in three specific areas: AIR (products and services in the respiratory field, from infants to adults), RARE (innovative solutions and personalized services to improve the quality of life of patients with rare and ultra-rare diseases) and CARE (products and services to support specialist care, personal care and well-being). Since 2019 Chiesi is a certified B Corp, while, in 2018, they have changed their legal status to a Benefit Company, realizing the desire to measure their impact on society and the environment, combining the need to generate value for the business to acting as a positive force for the community in which we live. Challenge Chiesi, one of the top 50 pharmaceutical companies in the world, is focused on addressing diseases through its three main therapeutic areas: AIR, RARE, and CARE. One of the core issues lie in the collection and processing of patient data for patient journey and clinical trials optimization. For Chiesi it is key to collect reliable data (GDPR and HIPAA compliant) from internal and external sources and elaborate/conditionate them to improve three specific phases of the patient journey: early diagnosis and prevention, therapy personalization/monitoring/efficacy, and a sustainable product lifecycle in their therapeutic areas. The goal is to develop a system that can collect and process data from internal sources, key stakeholders (such as clinics and hospitals), and external datasets to provide a digital solution (e.g., AI) that enables doctors to support patients throughout their journey, offering diagnoses, treatments and follow-ups, personalizing care pathways in hospitals, and enable patients to follow a correct treatment. The ideal solution could also support the doctor offering forecasts and suggestion for prevention and unlocking a way to allow the best patients recruitment in clinical trials. Objectives Scouting a data collection, conditioning, storage, and processing solution that supports medical operators in personalizing patient journey and patient care, from patient selection for clinical trials to prevention strategies and therapy customization, Looking for solutions with TRL 6 - Technology demonstrated in relevant environment, Chiesi is interested in collaborating with startups/scaleups to co-develop a PoC or to launch pilot projects together
Read more

About me

After a PhD in Industrial Biotechnology on metabolic engineering, I joined the Research Dept of the Italian association of medical devices companies in 2011.

From 2013 I was responsible for INNOVATION, dealing with startups, tech clusters, R&I grants at Eu, national and regional level.

In 2018 I reached Assolombarda as the general manager of the Lombardy Life Science Cluster which represents all regional healthcare private and public players – industry, research, hospitals.

I managed all activities and strategic projects, coordinating lobbying and communication activities, as well as events organization, supporting Cluster members in developing innovative projects and business, also at international level, helping them to find the right partners.

From Oct 2023 I am in Chiesi Center of Open Innovation and Competence, as innovation external ecosystem manager. The COIC works to find and manage external opportunities interesting for the development of inclusive and sustainable solutions.

My organisation

Chiesi Farmaceutici

https://www.chiesi.com/

Chiesi Group is a certified B Corp international biopharmaceutical group, headquartered in Parma, Italy, dedicated to the research, development and commercialisation of ethical products. Group sales peaked over €2.7 in 2022. Chiesi invested about 20% of the turnover in R&D. The Company, founded in 1935, employs ~ 6,500 people worldwide and has subsidiaries in 30 countries (in EU, USA, Mexico, Russia, Turkey, China, Brazil, Pakistan and Australia).

Chiesi is  looking for the expansion of its presence in Europe, US and Emerging Countries through licenses or asset/company acquisitions in the following areas:

  • All stage products in Respiratory and Neonatology;

  • Late Stage products in Special Care and Rare Diseases;

  • Marketed products in Consumer Healthcare & OTC.

Chiesi launched recently the Center of Open Innovation & Competence (COI&C) to, inter alia, scout early stage innovations in the above mentioned areas (TRL3-6) and to define innovative ways to engage esternal actors (Universities, incubators, accelerators, startups, investors, etc). COI&C is working starting from patient needs along the patient journey and is looking for inovations in Pharma (Biomarkers and Therapies), med-tech (early stage diagnosis, drug delivery devices and supporting tools/devices/wereables), digital health (education, monitoring, increased adherence, etc) and supporting technologies and solutions (clinical trial innovation and RWE, drug discovery platform conceived for the priority areas, etc)

Skills

  • biotechnology
  • innovation
  • Start-up
  • cluster
  • Open innovation